Increase in endoplasmic reticulum-associated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease

Neurobiology of Disease

Volumn 45, Issue 3, 2012, Pages 839-850

  Verhaar, Robin ^a   Drukarch, Benjamin ^a   Bol, John G J M ^a   Jongenelen, Cornelis A M ^a   Musters, René J P ^a   Wilhelmus, Micha M M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ER; Neuroblastoma; Parkinson's disease; SH SY5Y; Tissue transglutaminase

Indexed keywords

ALPHA SYNUCLEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

AMIDATION; ARTICLE; CATALYSIS; CATECHOLAMINE NERVE CELL; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; LIPOPHILICITY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CROSS LINKING; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; CALNEXIN; CALRETICULIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CYTOPLASM; CYTOSKELETAL PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; MICROSCOPY, ELECTRON, TRANSMISSION; NEUROBLASTOMA; NEURONS; PROTEIN DISULFIDE-ISOMERASES; THAPSIGARGIN; TRANSGLUTAMINASES; TRETINOIN; TUNICAMYCIN;

EID: 84856566340     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.10.012     Document Type: Article

References (90)

1. Akar U., et al. Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol. Cancer Res. 2007, 5:241-249.
2. Akimov S.S., Belkin A.M. Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood 2001, 98:1567-1576.
3. Andringa G., et al. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J. 2004, 18:932-934.
4. Bailey C.D., Johnson G.V. Developmental regulation of tissue transglutaminase in the mouse forebrain. J. Neurochem. 2004, 91:1369-1379.
5. 2+ store in the plasticity of central neurons. Trends Pharmacol. Sci. 2006, 27:78-84.
6. Beck K.E., et al. The role of tissue transglutaminase in 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in differentiated human SH-SY5Y neuroblastoma cells. Neurosci. Lett. 2006, 405:46-51.
7. Bellucci A., et al. Induction of the unfolded protein response by alpha-synuclein in experimental models of Parkinson disease. J. Neurochem. 2010, 116:588-605.
8. Betarbet R., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3:1301-1306.
9. Blum D., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 2001, 65:135-172.
10. Breve J.J., et al. Validated sandwich ELISA for the quantification of tissue transglutaminase in tissue homogenates and cell lysates of multiple species. J. Immunol. Methods 2008, 332:142-150.
11. Brumback A.C., et al. Using FM1-43 to study neuropeptide granule dynamics and exocytosis. Methods 2004, 33:287-294.
12. Cappelletti G., et al. The parkinsonism producing neurotoxin MPP+ affects microtubule dynamics by acting as a destabilising factor. FEBS Lett. 2005, 579:4781-4786.
13. Chevet E., et al. Calnexin phosphorylation: linking cytoplasmic signalling to endoplasmic reticulum lumenal functions. Semin. Cell Dev. Biol. 2010, 21:486-490.
14. Conn K.J., et al. Specific up-regulation of GADD153/CHOP in 1-methyl-4-phenyl-pyridinium-treated SH-SY5Y cells. J. Neurosci. Res. 2002, 68:755-760.
15. Conway K.A., et al. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 2000, 39:2552-2563.
16. D'Eletto M., et al. Transglutaminase 2 is involved in autophagosome maturation. Autophagy 2009, 5:1145-1154.
17. Drukarch B., et al. Glutathione is involved in the granular storage of dopamine in rat PC 12 pheochromocytoma cells: implications for the pathogenesis of Parkinson's disease. J. Neurosci. 1996, 16:6038-6045.
18. Duda J.E., et al. Neuropathology of synuclein aggregates. J. Neurosci. Res. 2000, 61:121-127.
19. Fanin M., et al. Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am. J. Pathol. 2006, 168:1309-1320.
20. Ferrera D., et al. Recombinase-deficient T cell development by selective accumulation of CD3 into lipid rafts. Eur. J. Immunol. 2008, 38:1148-1156.
21. Fesus L., Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem. Sci. 2002, 27:534-539.
22. Gocze P.M., Freeman D.A. Factors underlying the variability of lipid droplet fluorescence in MA-10 Leydig tumor cells. Cytometry 1994, 17:151-158.
23. Gorlach A., et al. The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid. Redox Signal. 2006, 8:1391-1418.
24. Griffin M., et al. Transglutaminases: nature's biological glues. Biochem. J. 2002, 368:377-396.
25. Guzman J.N., et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010, 468:696-700.
26. Hamilton R.L., et al. A rapid calcium precipitation method of recovering large amounts of highly pure hepatocyte rough endoplasmic reticulum. J. Lipid Res. 1999, 40:1140-1147.
27. Hasegawa G., et al. A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem. J. 2003, 373:793-803.
28. Holtz W.A., O'Malley K.L. Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons. J. Biol. Chem. 2003, 278:19367-19377.
29. Hoozemans J.J., et al. Activation of the unfolded protein response in Parkinson's disease. Biochem. Biophys. Res. Commun. 2007, 354:707-711.
30. Ikura K., et al. Amino acid sequence of guinea pig liver transglutaminase from its cDNA sequence. Biochemistry 1988, 27:2898-2905.
31. Ikura K., et al. Determination of amino- and carboxyl-terminal sequences of guinea pig liver transglutaminase: evidence for amino-terminal processing. Biochemistry 1989, 28:2344-2348.
32. Infante C., et al. GMAP-210, a cis-Golgi network-associated protein, is a minus end microtubule-binding protein. J. Cell Biol. 1999, 145:83-98.
33. Itano Y., Nomura Y. 1-Methyl-4-phenyl-pyridinium ion (MPP+) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma, SH-SY5Y cells, through different mechanisms. Brain Res. 1995, 704:240-245.
34. James R., et al. Disrupted in Schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly localizes to mitochondria. Mol. Cell. Neurosci. 2004, 26:112-122.
35. Jiang H., et al. Type I transglutaminase accumulation in the endoplasmic reticulum may be an underlying cause of autosomal recessive congenital ichthyosis. J. Biol. Chem. 2010, 285:31634-31646.
36. Jiang P., et al. ER stress response plays an important role in aggregation of alpha-synuclein. Mol. Neurodegener. 2010, 5:56.
37. Joshi S., et al. Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 2006, 25:240-247.
38. Junn E., et al. Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2047-2052.
39. Kamhi-Nesher S., et al. A novel quality control compartment derived from the endoplasmic reticulum. Mol. Biol. Cell 2001, 12:1711-1723.
40. Kitao Y., et al. Does ORP150/HSP12A protect dopaminergic neurons against MPTP/MPP(+)-induced neurotoxicity?. Antioxid. Redox Signal. 2007, 9:589-595.
41. Koh J.Y., et al. Staurosporine-induced neuronal apoptosis. Exp. Neurol. 1995, 135:153-159.
42. Kondratyev M., et al. PERK-dependent compartmentalization of ERAD and unfolded protein response machineries during ER stress. Exp. Cell Res. 2007, 313:3395-3407.
43. Lawe D.C., et al. The FYVE domain of early endosome antigen 1 is required for both phosphatidylinositol 3-phosphate and Rab5 binding. Critical role of this dual interaction for endosomal localization. J. Biol. Chem. 2000, 275:3699-3705.
44. Lesort M., et al. Tissue transglutaminase is increased in Huntington's disease brain. J. Neurochem. 1999, 73:2018-2027.
45. Li J., et al. The unfolded protein response regulator GRP78/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy in mammalian cells. Cell Death Differ. 2008, 15:1460-1471.
46. Lorand L., Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 2003, 4:140-156.
47. Luciani A., et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat. Cell Biol. 2010, 12:863-875.
48. Malorni W., et al. Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection. Curr. Pharm. Des. 2008, 14:278-288.
49. Muma N.A. Transglutaminase is linked to neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 2007, 66:258-263.
50. Murphy D.J. The biogenesis and functions of lipid bodies in animals, plants and microorganisms. Prog. Lipid Res. 2001, 40:325-438.
51. Nakaoka H., et al. Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 1994, 264:1593-1596.
52. Napolitano A., et al. Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr. Med. Chem. 2011, 18:1832-1845.
53. Nemes Z., et al. Transglutaminase-mediated intramolecular cross-linking of membrane-bound alpha-synuclein promotes amyloid formation in Lewy bodies. J. Biol. Chem. 2009, 284:27252-27264.
54. Ni M., Lee A.S. ER chaperones in mammalian development and human diseases. FEBS Lett. 2007, 581:3641-3651.
55. Nixon R.A. Autophagy in neurodegenerative disease: friend, foe or turncoat?. Trends Neurosci. 2006, 29:528-535.
56. Oda T., et al. Distinct mechanism of cell death is responsible for tunicamycin-induced ER stress in SK-N-SH and SH-SY5Y cells. Neurosci. Res. 2008, 60:29-39.
57. Oddi S., et al. Evidence for the intracellular accumulation of anandamide in adiposomes. Cell. Mol. Life Sci. 2008, 65:840-850.
58. Ou W.J., et al. Conformational changes induced in the endoplasmic reticulum luminal domain of calnexin by Mg-ATP and Ca2+. J. Biol. Chem. 1995, 270:18051-18059.
59. Perry M.J., Haynes L.W. Localization and activity of transglutaminase, a retinoid-inducible protein, in developing rat spinal cord. Int. J. Dev. Neurosci. 1993, 11:325-337.
60. Piacentini M., et al. "Tissue" transglutaminase is specifically expressed in neonatal rat liver cells undergoing apoptosis upon epidermal growth factor-stimulation. Cell Tissue Res. 1991, 263:227-235.
61. Piacentini M., et al. Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress. J. Neurochem. 2002, 81:1061-1072.
62. Piacentini M., et al. Type 2 transglutaminase and cell death. Prog. Exp. Tumor Res. 2005, 38:58-74.
63. Pinkas D.M., et al. Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007, 5:e327.
64. Plutner H., et al. Morphological analysis of protein transport from the ER to Golgi membranes in digitonin-permeabilized cells: role of the P58 containing compartment. J. Cell Biol. 1992, 119:1097-1116.
65. Rodolfo C., et al. Tissue transglutaminase is a multifunctional BH3-only protein. J. Biol. Chem. 2004, 279:54783-54792.
66. Rutkowski D.T., Kaufman R.J. That which does not kill me makes me stronger: adapting to chronic ER stress. Trends Biochem. Sci. 2007, 32:469-476.
67. Ryu E.J., et al. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J. Neurosci. 2002, 22:10690-10698.
68. Samanta K., et al. Localization of m-calpain and calpastatin and studies of their association in pulmonary smooth muscle endoplasmic reticulum. Biochim. Biophys. Acta 2007, 1770:1297-1307.
69. Schaertl S., et al. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J. Biomol. Screen. 2010, 15:478-487.
70. Schapira A.H. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008, 7:97-109.
71. Segers-Nolten I.M., et al. Tissue transglutaminase modulates alpha-synuclein oligomerization. Protein Sci. 2008, 17:1395-1402.
72. Sheehan J.P., et al. MPP+ induced apoptotic cell death in SH-SY5Y neuroblastoma cells: an electron microscope study. J. Neurosci. Res. 1997, 48:226-237.
73. Silva R.M., et al. CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model of parkinsonism. J. Neurochem. 2005, 95:974-986.
74. Singh U.S., et al. Identification and biochemical characterization of an 80kilodalton GTP-binding/transglutaminase from rabbit liver nuclei. Biochemistry 1995, 34:15863-15871.
75. Spillantini M.G., et al. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
76. Surmeier D.J. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 2007, 6:933-938.
77. 2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:2466-2470.
78. Verhaar R., et al. Blockade of enzyme activity inhibits tissue transglutaminase-mediated transamidation of alpha-synuclein in a cellular model of Parkinson's disease. Neurochem. Int. 2011, 58:785-793.
79. Vermes I., et al. Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov. Disord. 2004, 19:1252-1254.
80. Wang H.Q., Takahashi R. Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease. Antioxid. Redox Signal. 2007, 9:553-561.
81. West G.J., et al. Adrenergic, cholinergic, and inactive human neuroblastoma cell lines with the action-potential Na+ ionophore. Cancer Res. 1977, 37:1372-1376.
82. Wilhelmus M.M., et al. Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain. Brain Pathol. 2011, 21:130-139.
83. Williams A., et al. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications. Curr. Top. Dev. Biol. 2006, 76:89-101.
84. Winklhofer K.F., Haass C. Mitochondrial dysfunction in Parkinson's disease. Biochim. Biophys. Acta 2010, 1802:29-44.
85. Winner B., et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4194-4199.
86. Wong H.N., et al. Conserved in vivo phosphorylation of calnexin at casein kinase II sites as well as a protein kinase C/proline-directed kinase site. J. Biol. Chem. 1998, 273:17227-17235.
87. Yang Y.S., et al. Reticulon-4A (Nogo-A) redistributes protein disulfide isomerase to protect mice from SOD1-dependent amyotrophic lateral sclerosis. J. Neurosci. 2009, 29:13850-13859.
88. Zemskov E.A., et al. The role of tissue transglutaminase in cell-matrix interactions. Front. Biosci. 2006, 11:1057-1076.
89. Zemskov E.A., et al. Cell-surface transglutaminase undergoes internalization and lysosomal degradation: an essential role for LRP1. J. Cell Sci. 2007, 120:3188-3199.
90. Zhang J., et al. Modulation of the in situ activity of tissue transglutaminase by calcium and GTP. J. Biol. Chem. 1998, 273:2288-2295.